microdose glp 1 benefits Microdosing GLP-1 Microdosing GLP-1 for Weight Loss

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Safety of Semaglutide [published correction appears in Front Endocrinol (Lausanne)

95% CI 0.66 1.14

In summary, the intricate interplay of metabolic abnormalities, inflammatory responses, and hormonal influences in obesity and diabetes underscores their significant impact on cancer risk and mortality

Clinical trial data provides objective evidence about efficacy (24.2% weight loss at 48 weeks), safety (88.8% completion rate), side effects (peak at weeks 6-8, resolve by week 12 for most), and discontinuation outcomes (70-80% regain over 12-18 months, not immediately)